We are live on ! Find out more
TSHA icon

Taysha Gene Therapies
TSHA

52 hedge funds and large institutions have $43.8M invested in Taysha Gene Therapies in 2022 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 21 increasing their positions, 9 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 9

122% more call options, than puts

Call options by funds: $189K | Put options by funds: $85K

62% more capital invested

Capital invested by funds: $27M → $43.8M (+$16.8M)

2.87% less ownership

Funds ownership: 33.9% → 31.03% (-2.9%)

4% less funds holding

Funds holding: 54 → 52 (-2)

13% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 16

Holders
52
Holders Change
-2
Holders Change %
-3.7%
% of All Funds
0.84%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
14
Increased
21
Reduced
9
Closed
16
Calls
$189K
Puts
$85K
Net Calls
+$104K
Net Calls Change
-$87K

Top Buyers

Rank Fund Capital Flow
1
NCM
Nantahala Capital Management
Connecticut
+$2.81M
2
TCM
Tybourne Capital Management
Hong Kong
+$2.02M
3
LCM
Laurion Capital Management
New York
+$1.72M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$982K
5
AG
Artal Group
Luxembourg
+$810K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$651K
2
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$207K
3
Two Sigma Advisers
Two Sigma Advisers
New York
-$169K
4
State of Wisconsin Investment Board
State of Wisconsin Investment Board
Wisconsin
-$167K
5
Fidelity Investments
Fidelity Investments
Massachusetts
-$164K
Name Holding Trade Value Shares
Change 		Change in
Stake
MCC
51
Money Concepts Capital
Florida
$260 +$233 +115 New
D.E. Shaw & Co
52
D.E. Shaw & Co
New York
– -$207K -107,274 Closed
Two Sigma Advisers
53
Two Sigma Advisers
New York
– -$169K -87,700 Closed
State of Wisconsin Investment Board
54
State of Wisconsin Investment Board
Wisconsin
– -$167K -86,600 Closed
E
55
Ergoteles
New York
– -$148K -76,743 Closed
TSW
56
Thompson Siegel & Walmsley
Virginia
– -$108K -56,100 Closed
Two Sigma Investments
57
Two Sigma Investments
New York
– -$84K -43,378 Closed
HSBC Holdings
58
HSBC Holdings
United Kingdom
– -$32K -16,570 Closed
Qube Research & Technologies (QRT)
59
Qube Research & Technologies (QRT)
United Kingdom
– -$31K -16,000 Closed
OQS
60
Occudo Quantitative Strategies
Florida
– -$28K -14,679 Closed
Bank of New York Mellon
61
Bank of New York Mellon
New York
– -$22K -11,295 Closed
SSA
62
Schonfeld Strategic Advisors
New York
– -$22K -11,000 Closed
6CM
63
683 Capital Management
New York
– -$19K -10,000 Closed
Citigroup
64
Citigroup
New York
– -$1K -635 Closed
CUAMC
65
China Universal Asset Management Company
China
– -$1K -385 Closed
Simplex Trading
66
Simplex Trading
Illinois
– -$703 -347 Closed
Royal Bank of Canada
67
Royal Bank of Canada
Ontario, Canada
– +$10 +5 +26%
1 2
3

TSHA Hedge Fund Activity: Q4 2022 in Review

52 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Taysha Gene Therapies (TSHA) for Q4 2022, worth a combined $43.8M — up 62% from $27M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of TSHA and 14 opened new positions — a net loss of 2 holders — while 9 trimmed existing stakes and 21 added.

The largest buyer was Nantahala Capital Management, adding an estimated $2.81M. The largest seller was BlackRock, cutting an estimated $651K.

  • 52 institutional investors held Taysha Gene Therapies (TSHA) as of Q4 2022, down from 54 in Q3 2022.
  • Funds reported $43.8M of Taysha Gene Therapies stock for Q4 2022, up 62% quarter-over-quarter.
  • 14 funds opened new Taysha Gene Therapies positions in Q4 2022 and 16 closed out, a net change of -2 holders.
  • The largest Taysha Gene Therapies buyer in Q4 2022 was Nantahala Capital Management, an estimated $2.81M added.
  • The largest Taysha Gene Therapies seller in Q4 2022 was BlackRock, an estimated $651K sold.

Based on aggregated 13F filings for Q4 2022.